Short answer
ACTUATE THERAPEUTICS, INC. (ACTU) filed an 8-K current report with the SEC on July 17, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq MVLS deficiency after market value remained below $50 million from June 1–July 14, 2026.
- This filing includes Item 3.01, an item that often signal trouble.
ACTUATE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Nasdaq MVLS deficiency after market value remained below $50 million from June 1–July 14, 2026
- Common stock remains listed and trading on Nasdaq Global Market under ACTU
- 180-day remediation period runs through January 11, 2027
- Compliance requires MVLS of at least $50 million for 10 consecutive business days
- Failure could trigger delisting proceedings, appeal, or transfer to Nasdaq Capital Market
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACTUATE THERAPEUTICS, INC. 8-K filings
Get the next ACTU 8-K as it lands
Follow ACTU for push alerts, or ask the research agent what this filing means.